Geojit's research report on Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd (TPL) is engaged in the research, development, manufacture and marketing of generic pharmaceutical formulations in India, the US, Germany, Brazil and other countries. The company offers products in various therapeutic areas. Consolidated revenue grew 10.3% YoY to Rs. 2,859cr in Q1FY25, driven by strong growth in India and Germany markets. EBITDA increased 14.3% YoY to Rs. 904cr, and the margin expanded 110bps to 31.6%, led by the company’s cost optimisation efforts.
Outlook
given consistent cost-efficiency measures and falling raw material prices. Hence, we upgrade BUY rating on the stock with a revised target price of Rs. 3,590 based on 47x FY26E adjusted EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
